Journal September 26, 2026 4 min read

How Does Brown Adipose Tissue Work?

Brown adipose tissue (BAT) is a thermogenic fat depot that dissipates energy as heat. This page outlines the molecular pathways, animal models, and human studies that define its function.

peptides-pro Editorial

Brown adipose tissue (BAT), also called brown fat, is a specialized thermogenic adipose depot whose adipocytes contain multiple lipid droplets and densely packed mitochondria. Unlike white adipose tissue (WAT), which stores energy, BAT oxidizes fatty acids to produce heat. In humans, functional BAT is found in the cervical, supraclavicular, and paravertebral regions, and its activity declines with age [6]. The tissue is defined functionally rather than by a single molecular identifier: its thermogenic capacity depends on uncoupling protein 1 (UCP1), which is not listed with a sequence or formula in the evidence provided here.

The work described in this evidence centres on the transforming growth factor-beta (TGF-β) superfamily and its signalling through SMAD2/3, alongside adrenergic and metabolic regulators including beta3-adrenergic receptors, erythropoietin (EPO), and nicotinamide adenine dinucleotide (NAD+) [3][5][6][7].

Research Studies

FSTL1 and WAT browning in male mice

Follistatin-like 1 (FSTL1) is an adipokine implicated in WAT adipogenesis, BAT involution, and thermogenesis. In male mice housed at ambient room temperature, FSTL1 overexpression induced WAT browning, enhanced energy metabolism, and promoted glucose uptake. Overexpression specifically in WAT prevented metabolic dysfunction in mice with diet-induced obesity, while FSTL1-deficient mice exhibited cold intolerance and were prone to obesity. FSTL1 could not directly induce the browning response on its own, indicating an indirect mechanism [1].

Follistatin and atherosclerosis in mice

Follistatin (FST) binds and neutralizes TGF-β superfamily members, regulating skeletal muscle, adipose, and bone homeostasis. FST promotes adipose browning and enhances energy metabolism in mice, improving plasma lipid profiles. Transcriptomic and metabolomic analysis of the Hybrid Mouse Diversity Panel found that Fst expression was negatively correlated with aortic lesion area, prompting investigation of its anti-atherogenic potential [2].

GDF-11 and cold-induced browning in mice and 3T3-L1 cells

Growth differentiation factor 11 (GDF-11) is a circulating TGF-β superfamily member. In mice exposed to cold, GDF-11 expression and SMAD2/3 activation were assessed in BAT, visceral and subcutaneous WAT, and skeletal muscle. The study combined in vivo results with in vitro approaches using 3T3-L1 cells [3].

Erythropoietin and adipose lipid handling

EPO is best known as the regulator of erythrocyte production; mice lacking EPO or its receptor die in utero from severe anemia. Beyond haematopoiesis, EPO influences glucose and fat metabolism in adipose tissue, skeletal muscle, and liver. In WAT, BAT, and skeletal muscle, EPO enhances lipolysis while inhibiting lipogenic gene expression [5].

Beta3-adrenergic receptor agonists and BAT adaptation

A clinical study examined the physiological responses and adaptation of BAT to chronic treatment with beta3-adrenergic receptor agonists in adults aged 18–40 with a body mass index between 18 and 40. The protocol included baseline metabolic testing, exercise testing, and PET imaging with a radioactive tracer [7].

NAD+ metabolism in human BAT

Brown fat functionality declines with age in human adults, a change associated with unhealthy weight gain, particularly central obesity. A clinical project is investigating whether declining availability of NAD+, a molecule central to several metabolic processes, contributes to the decline in brown fat metabolism, and whether NAD+-based molecules can modify it [6].

Thyroid hormones and BAT in thyrotoxicosis

An observational study is evaluating the effect of thyroid hormones on BAT in humans with thyrotoxicosis, using FDG-PET/CT, indirect calorimetry, and fat biopsies during the acute phase and after treatment, when patients are euthyroid. The hypothesis is that high circulating T3 levels affect the amount and function of BAT [8].

Capsinoid supplementation in obese adolescents

BAT activation from WAT is under investigation as a strategy for obesity and its metabolic complications. A clinical study is examining capsinoid supplementation in obese adolescents, building on the finding that functional BAT in humans was identified within the last 5–10 years. BAT is described as anti-obesogenic rather than storage-oriented, owing to its high metabolic and energetic activity [4].

EGCG and BAT-independent thermogenesis in mice

Epigallocatechin gallate (EGCG) has anti-obesity effects, but whether it acts through BAT was previously unknown. Work in this area reports that EGCG triggered a BAT-independent thermogenic switch and remodelled the immune microenvironment in subcutaneous adipose tissue [9].

Comparison of Selected Modulators

Agent	Model / population	Reported effect
FSTL1	Male mice, ambient temperature	WAT browning, enhanced energy metabolism, glucose uptake [1]
Follistatin	Mice; HMDP transcriptomics	Adipose browning, improved lipid profile; Fst negatively correlated with aortic lesion area [2]
GDF-11	Cold-exposed mice; 3T3-L1 cells	SMAD2/3 activation assessed across BAT, WAT, muscle [3]
EPO	Adipose, muscle, liver	Enhanced lipolysis, inhibited lipogenic gene expression [5]

If you are reading this for personal health reasons

The materials described here are sold for laboratory research only, and we do not provide dosing or medical guidance. Nothing on this page is a recommendation for human use. Anyone considering a compound for themselves should speak to a licensed clinician.